Suppr超能文献

源自土耳其和克里米亚的家族性地中海热儿科患者的比较。

The Comparison of Pediatric Patients with Familial Mediterranean Fever Originated from Turkey and Crimea.

作者信息

Kostik Mikhail, Akca Kaya Ummusen, Zhogova Olga V, Sag Erdal, Suspitsin Evgeny N, Nizhnik Viktoriya I, Tumakova Anastasiya V, Ivanovskiy Sergey V, Lagunova Natalia V, Bilginer Yelda, Ozen Seza

机构信息

St. Petersburg State Pediatric Medical University, Hospital Pediatry, Saint-Petersburg, Russia.

Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

出版信息

Turk Arch Pediatr. 2022 Sep;57(5):551-557. doi: 10.5152/TurkArchPediatr.2022.22106.

Abstract

OBJECTIVE

We aimed to evaluate the clinical and laboratory features and MEFV allele distribution in Crimean Tatar familial Mediterranean fever patients and to compare them with Turkish familial Mediterranean fever patients and healthy controls.

MATERIALS AND METHODS

All newly diagnosed familial Mediterranean fever patients with Crimean Tatar nationality (n = 18) in Children's Regional Hospital in Simferopol were enrolled in the study and were compared to 40 familial Mediterranean fever cases followed up at Hacettepe University, Ankara, Turkey. The distribution of MEFV alleles was assessed in the 127 unrelated healthy Crimean Tatar adults aged 20 years or more from different parts of the Crimea peninsula.

RESULTS

Age and gender distribution, the frequency of colchicine resistance, and colchicine intolerance were similar between Turkish and Crimean Tatar children with familial Mediterranean fever. The duration of familial Mediterranean fever attack was shorter in Turkish patients than in Crimean Tatar (2.0 vs. 3.0 days, P < .001). Chest pain was more frequent in Turkish familial Mediterranean fever patients, whereas arthralgia, arthritis, and erysipeloid rash were more common in Crimean TatarT. MEFV allele distribution in Crimean Tatar was M694V-81%, M680I and V726A 9.5% both, and 68.6%, 14.3%, and 12.9% in Turkish, consequently. Homozygous carriers were 11%, compound-heterozygous was 6%, and heterozygous was 83%, compared to Turkish being 45%, 30%, and 25%, respectively. The allele distribution in healthy Crimean Tatar and Turkish was 10.2% and M694V was 7.1%, M680I was 1.6%, and V726A was 1.6%.

CONCLUSION

The similar MEFV allele prevalence in both populations suggests the high prevalence of familial Mediterranean fever and the high number of undiagnosed patients in the Crimea peninsula. Younger age at onset, shorter duration of attacks, the prevalence of articular involvement, and erysipeloid rash were distinctive features of familial Mediterranean fever in Crimean Tatar.

摘要

目的

我们旨在评估克里米亚鞑靼族家族性地中海热患者的临床和实验室特征以及MEFV等位基因分布,并将其与土耳其家族性地中海热患者及健康对照进行比较。

材料与方法

辛菲罗波尔儿童地区医院所有新诊断的克里米亚鞑靼族家族性地中海热患者(n = 18)纳入本研究,并与土耳其安卡拉哈杰泰佩大学随访的40例家族性地中海热病例进行比较。对来自克里米亚半岛不同地区的127名20岁及以上无亲缘关系的健康克里米亚鞑靼族成年人评估MEFV等位基因分布。

结果

土耳其和克里米亚鞑靼族家族性地中海热儿童的年龄和性别分布、秋水仙碱耐药频率及秋水仙碱不耐受情况相似。土耳其患者家族性地中海热发作的持续时间比克里米亚鞑靼族患者短(2.0天对3.0天,P <.001)。胸痛在土耳其家族性地中海热患者中更常见,而关节痛、关节炎和丹毒样皮疹在克里米亚鞑靼族中更常见。克里米亚鞑靼族中MEFV等位基因分布为M694V - 81%,M680I和V726A均为9.5%,而在土耳其分别为68.6%、14.3%和12.9%。纯合子携带者在克里米亚鞑靼族中为11%,复合杂合子为6%,杂合子为83%,而在土耳其分别为45%、30%和

相似文献

1
The Comparison of Pediatric Patients with Familial Mediterranean Fever Originated from Turkey and Crimea.
Turk Arch Pediatr. 2022 Sep;57(5):551-557. doi: 10.5152/TurkArchPediatr.2022.22106.
4
MEFV mutations and their relation to major clinical symptoms of Familial Mediterranean Fever.
Gene. 2017 Aug 30;626:9-13. doi: 10.1016/j.gene.2017.05.013. Epub 2017 May 5.
5
MEFV mutation frequencies in a Turkish cohort with low prevalence of familial Mediterranean fever.
Turk J Med Sci. 2021 Aug 30;51(4):1702-1705. doi: 10.3906/sag-2009-119.
6
MEFV gene compound heterozygous mutations in familial Mediterranean fever phenotype: a retrospective clinical and molecular study.
Nephrol Dial Transplant. 2010 Aug;25(8):2520-3. doi: 10.1093/ndt/gfp632. Epub 2009 Nov 23.
7
Familial Mediterranean fever in Jordanian Children: single centre experience.
Mediterr J Rheumatol. 2018 Dec 18;29(4):211-216. doi: 10.31138/mjr.29.4.211. eCollection 2018 Dec.
9
MEFV heterogeneity in Turkish Familial Mediterranean Fever patients.
Mol Biol Rep. 2010 Jan;37(1):355-8. doi: 10.1007/s11033-009-9779-9.
10
Real-Life Data From the Largest Pediatric Familial Mediterranean Fever Cohort.
Front Pediatr. 2022 Jan 20;9:805919. doi: 10.3389/fped.2021.805919. eCollection 2021.

本文引用的文献

1
Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):30-36. doi: 10.55563/clinexprheumatol/815tdt. Epub 2021 Jun 21.
2
Sacroiliitis in children and adolescents with familial Mediterranean fever.
Adv Rheumatol. 2021 Jun 5;61(1):29. doi: 10.1186/s42358-021-00188-2.
3
Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach.
Rheumatology (Oxford). 2021 Aug 2;60(8):3799-3808. doi: 10.1093/rheumatology/keaa863.
4
Does Age at Onset Affect the Clinical Presentation of Familial Mediterranean Fever in Children?
J Clin Rheumatol. 2022 Jan 1;28(1):e125-e128. doi: 10.1097/RHU.0000000000001637.
5
Erysipelas-like erythema in children with familial Mediterranean fever.
Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl 127(5):101-104. Epub 2020 Oct 28.
7
Evaluation of familial Mediterranean fever patients concomitant with juvenile spondyloarthropathy.
Mod Rheumatol. 2021 May;31(3):718-724. doi: 10.1080/14397595.2020.1812809. Epub 2020 Sep 7.
8
Comparison of clinical features in FMF patients according to severity scores: An analysis with the ISSF scoring system.
Eur J Rheumatol. 2020 Apr;7(2):68-70. doi: 10.5152/eurjrheum.2020.19136. Epub 2020 Apr 1.
10
Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry.
Rheumatology (Oxford). 2020 Nov 1;59(11):3324-3329. doi: 10.1093/rheumatology/keaa121.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验